Paediatric ependymomas: should we avoid radiotherapy?

Lancet Oncology

Volumn 8, Issue 8, 2007, Pages 665-666

  Bouffet, Eric ^a   Tabori, Uri ^a   Bartels, Ute ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; METHOTREXATE; TELOMERASE REVERSE TRANSCRIPTASE;

ACCURACY; BRAIN RADIATION; BRAIN SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG RESPONSE; EPENDYMOMA; HUMAN; LETTER; PATIENT SAFETY; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; EPENDYMOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 34547540654     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70213-9     Document Type: Letter

References (10)

1. Grundy R., Wilne S., Weston C., et al. Primary post-operative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8 (2007) 696-705
2. Duffner P., Krischer J., Sanford R., et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 28 (1998) 215-222
3. Grill J., Le Deley M., Gambarelli D., et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19 (2001) 1288-1296
4. Geyer J., Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23 (2005) 7621-7631
5. Zacharoulis S., Levy A., Chi S., et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49 (2007) 34-40
6. Bouffet E., Perilongo G., Canete A., and Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30 (1998) 319-329
7. Merchant T., Mulhern R., Krasin M., et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22 (2004) 3156-3162
8. Observation or radiation therapy and/or chemotherapy and second surgery in treating children who have undergone surgery for ependymoma. http://www.cancer.gov/search/viewclinicaltrials.aspx?version=healthprofe ssional&cdrid=69086 (accessed July 4, 2007).
9. Gilbertson R., Bentley L., Hernan R., et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8 (2002) 3054-3064
10. Tabori U., Ma J., Carter M., et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 24 (2006) 1522-1528